X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES LIMITED Quarterly Results - Equitymaster
 
VENUS REMEDIES LIMITED  - Last 8 Quarters  (VSRM)

Here are the latest quarterly results of VENUS REMEDIES. For more details, see the VENUS REMEDIES financial fact sheet and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
 Interim Results
No. of Months
Qtr. Ending
3
Mar-15
3
Jun-15
3
Sep-15
3
Dec-15
3
Mar-16
3
Jun-16
3
Sep-16
3
Dec-16
8-Qtr Chart
Click to enlarge
Net Sales Rs m9899891,0599849941,0311,071854 
Other income Rs m21114122 
Turnover Rs m9919901,0619859981,0331,073856 
Expenses Rs m870797856804774853878659 
Gross profit Rs m119192204180220179193195 
Depreciation Rs m17110010210210299100115 
Interest Rs m1569187821077083103 
Profit before tax Rs m-207216-3151211-21 
Tax Rs m000018000 
Profit after tax Rs m-207216-3-41211-21 
Gross profit margin %12.019.419.218.322.117.318.022.8 
Effective tax rate %0.00.00.00.0124.00.00.00.0 
Net profit margin %-20.90.21.5-0.3-0.41.11.1-2.5 
Diluted EPS Rs -18.1 0.2 1.4 -0.2 -0.3 1.0 1.0 -1.8  
Diluted EPS (TTM) Rs 1.8 -7.0 -14.6 -16.7 1.0 1.9 1.5 -0.1  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster



Today's Market

Sensex Finishes Lower; Metal & FMCG Stocks Drag(Closing)

Share markets in India finished on a weak note as investors continued to book profits ahead of the April F&O expiry. At the closing bell, the BSE Sensex closed lower by 104 points.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

VENUS REMEDIES SHARE PRICE


Apr 27, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE VENUS REMEDIES WITH

MARKET STATS